RxDoctor Payments Data

Kyra Vineyard

Family Medicine · Tulsa, OKNPI 1225005895

Payments from drug & device makers

$6,868in general payments, 2019–2025

Across 259 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$865
  • Novo Nordisk$722
  • AbbVie$693
  • Bayer$655
  • Teva Pharmaceuticals USA, Inc.$303
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$6,82699%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,868 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol165$105,278
MounjaroTirzepatide88$99,277
Xigduo XrDapaglifloz Propaned/Metformin96$60,231
Synjardy XrEmpagliflozin/Metformin Hcl53$51,373
RybelsusSemaglutide21$33,620
JardianceEmpagliflozin42$30,476
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$30,145
Breo ElliptaFluticasone/Vilanterol36$23,030
TrulicityDulaglutide24$21,885
KerendiaFinerenone19$17,706
OzempicSemaglutide16$15,267
VascepaIcosapent Ethyl22$12,173
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,062
XareltoRivaroxaban12$8,542
Hydroxychloroquine Sulfate143$5,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$865$121,162112 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,029$114,340179 claims
Boehringer IngelheimSynjardy Xr, Jardiance$264$81,84995 claims
GSKTrelegy Ellipta, Breo Ellipta$143$53,17565 claims
Novo NordiskRybelsus, Ozempic$722$48,88737 claims
BayerKerendia$655$17,70619 claims
AbbVieViibryd, Synthroid$693$8,51170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →